ENOS and caveolin-1 gene polymorphisms interaction and intima media thickness: A proof of concept study in ESRD patients

American Journal of Hypertension

Volumn 25, Issue 1, 2012, Pages 103-108

  Testa, Alessandra ^a   Spoto, Belinda ^a   Sanguedolce, Maria Cristina ^a   Parlongo, Rosa M ^a   Pisano, Anna ^a   Tripepi, Giovanni ^a   Benedetto, Francesco A ^b   Mallamaci, Francesca ^a   Zoccali, Carmine ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b Morelli Hospital   (Italy)

Author keywords

blood pressure; cardiovascular risk; caveolin 1; end stage renal disease; endothelial nitric oxide synthase; genetics; hypertension

Indexed keywords

CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADULT; ALLELE; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; ECHOGRAPHY; FEMALE; GENE INTERACTION; GENETIC RISK; GENOTYPE; HOMOZYGOTE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CAVEOLIN 1; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, GENETIC;

EID: 83655191960     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.178     Document Type: Article

References (21)

1. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24:611-619.
2. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113-2117. (Pubitemid 34094901)
3. Belinda S, Francesco AB, Alessandra T, Giovanni T, Francesca M, Renke M, Boeger RH, Zoccali C. Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease. Am J Hypertens 2005; 18:1549-1555. (Pubitemid 41814675)
4. Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, Maas R, Boeger R, Zoccali C. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J Hypertens 2005; 23:1825-1830. (Pubitemid 41830422)
5. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest 2001; 108:1553-1561. (Pubitemid 33144862)
6. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou H Jr, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276:38121-38138.
7. Santibanez JF, Blanco FJ, Garrido-Martin EM, Sanz-Rodriguez F, del Pozo MA, Bernabeu C. Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae. Cardiovasc Res 2008; 77:791-799. (Pubitemid 351301871)
8. Grainger DJ. TGF-beta and atherosclerosis in man. Cardiovasc Res 2007; 74:213-222.
9. Joshi MS, Mineo C, Shaul PW, Bauer JA. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J 2007; 21:2655-2663. (Pubitemid 47372733)
10. Moore J, McKnight AJ, Simmonds MJ, Courtney AE, Hanvesakul R, Brand OJ, Briggs D, Ball S, Cockwell P, Patterson CC, Maxwell AP, Gough SC, Borrows R. Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. JAMA 2010; 303:1282-1287.
11. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001; 12:2458-2464. (Pubitemid 33021124)
12. Khattar RS, Acharya DU, Kinsey C, Senior R, Lahiri A. Longitudinal association of ambulatory pulse pressure with left ventricular mass and vascular hypertrophy in essential hypertension. J Hypertens 1997; 15:737-743. (Pubitemid 27249989)
13. Benedetto FA, Tripepi G, Mallamaci F, Zoccali C. Rate of atherosclerotic plaque formation predicts cardiovascular events in ESRD. J Am Soc Nephrol 2008; 19:757-763.
14. Rossi A, Baldo-Enzi G, Calabrò A, Sacchetto A, Pessina AC, Rossi GP. The reninangiotensin-aldosterone system and carotid artery disease in mild-to-moderate primary hypertension. J Hypertens 2000; 18:1401-1409.
15. Miller SA, Dykes DD, Polesky HF. Salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16:1215.
16. Steverberg EW. Clinical Prediction Models. A Practical Approach to Development, Validation, and Updating. Springer: New York, 2009. pp. 93-98 and 303-304.
17. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51:1678-1695. (Pubitemid 27252735)
18. Michel JB, Feron O, Sacks D, Michel T. Reciprocal regulation of endothelial nitric?oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem 1997; 272:15583-15586. (Pubitemid 27265522)
19. Rahman A, Swärd K. The role of caveolin-1 in cardiovascular regulation. Acta Physiol (Oxf ) 2009; 195:231-245.
20. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004; 109:1359-1365. (Pubitemid 38387821)
21. Hingorani AD. Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep 2003; 5:19-25. (Pubitemid 38898928)